Papers/PMID:35138351
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.
JAMA dermatology2022The record
5 findings · 1 compound · 5 endpoints · 4 null
What it reported
How to read these marksWhat moved
1 finding
spironolactone — decreases prostate cancer incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“There was an association between spironolactone use and decreased risk of prostate cancer (RR, 0.79; 95% CI, 0.68-0.90; certainty of evidence very low).”
Quoted verbatim from Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.. - Study
- meta-analysis
- Population
- Men and women aged 18 years and older ever exposed to spironolactone, pooled from seven observational studies
Effect 0.79 risk ratio, 95% CI 0.68 to 0.9
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.2022PMID:35138351Permalink
What did not
4 findings
spironolactone — no detected effect on urinary bladder cancer incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“There was no statistically significant association between spironolactone use and risk of ovarian cancer (RR, 1.52; 95% CI, 0.84-2.20; certainty of evidence very low), bladder cancer (RR, 0.89; 95% CI, 0.71-1.07; certainty of evidence very low), kidney cancer (RR, 0.96; 95% CI, 0.85-1.07; certainty of evidence low), gastric cancer (RR, 1.02; 95% CI, 0.80-1.24; certainty of evidence low), or esophageal cancer (RR, 1.09; 95% CI, 0.91-1.27; certainty of evidence low).”
Quoted verbatim from Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.. - Study
- meta-analysis
- Population
- Men and women aged 18 years and older ever exposed to spironolactone, pooled from seven observational studies
Effect 0.89 risk ratio, 95% CI 0.71 to 1.07
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.2022PMID:35138351Permalink
spironolactone — no detected effect on gastric cancer incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“There was no statistically significant association between spironolactone use and risk of ovarian cancer (RR, 1.52; 95% CI, 0.84-2.20; certainty of evidence very low), bladder cancer (RR, 0.89; 95% CI, 0.71-1.07; certainty of evidence very low), kidney cancer (RR, 0.96; 95% CI, 0.85-1.07; certainty of evidence low), gastric cancer (RR, 1.02; 95% CI, 0.80-1.24; certainty of evidence low), or esophageal cancer (RR, 1.09; 95% CI, 0.91-1.27; certainty of evidence low).”
Quoted verbatim from Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.. - Study
- meta-analysis
- Population
- Men and women aged 18 years and older ever exposed to spironolactone, pooled from seven observational studies
Effect 1.02 risk ratio, 95% CI 0.8 to 1.24
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.2022PMID:35138351Permalink
spironolactone — no detected effect on oesophageal cancer incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“There was no statistically significant association between spironolactone use and risk of ovarian cancer (RR, 1.52; 95% CI, 0.84-2.20; certainty of evidence very low), bladder cancer (RR, 0.89; 95% CI, 0.71-1.07; certainty of evidence very low), kidney cancer (RR, 0.96; 95% CI, 0.85-1.07; certainty of evidence low), gastric cancer (RR, 1.02; 95% CI, 0.80-1.24; certainty of evidence low), or esophageal cancer (RR, 1.09; 95% CI, 0.91-1.27; certainty of evidence low).”
Quoted verbatim from Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.. - Study
- meta-analysis
- Population
- Men and women aged 18 years and older ever exposed to spironolactone, pooled from seven observational studies
Effect 1.09 risk ratio, 95% CI 0.91 to 1.27
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.2022PMID:35138351Permalink
spironolactone — no detected effect on breast cancer incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“No statistically significant association was observed between spironolactone use and risk of breast cancer (risk ratio [RR], 1.04; 95% CI, 0.86-1.22; certainty of evidence very low).”
Quoted verbatim from Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.. - Study
- meta-analysis
- Population
- Men and women aged 18 years and older ever exposed to spironolactone, pooled from seven observational studies
Effect 1.04 risk ratio, 95% CI 0.86 to 1.22
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.2022PMID:35138351Permalink